In a research report released today, Brean Capital analyst Difei Yang reiterated a Buy rating on Horizon Pharma (NASDAQ:HZNP) with a price target …
Brean Capital analyst Difei Yang initiated coverage on shares of Horizon Pharma (NASDAQ:HZNP) with a Buy rating and a price target of $18, which represents a …